PET-CT scan cost for kidney cancer — what the fee covers, and what it does not

CION publishes the rate rather than quoting it over the phone. A whole-body PET-CT is ₹9,999 on an analogue scanner and ₹14,950 on a digital one, and across the referral network the published band runs from ₹9,999 to about ₹16,000 for a whole-body study. Those are indicative figures, not a quotation, and they are confirmed in writing before anything is booked. The important caution is that the scan fee is not the bill. A contrast CT or MRI of the kidneys, the biopsy, the blood and kidney function tests and the consultation are separate items — and in kidney cancer it is the contrast scan, not the PET-CT, that the diagnosis usually rests on.

The difference is detector technology, and it shows up as resolution. A digital scanner picks up smaller lesions and generally scans faster, which is why it is priced at ₹14,950 against ₹9,999. Whether that difference is worth paying for depends entirely on the question being asked. If the scan is mapping disease already known to have spread, the extra resolution may add little. If the whole point is to resolve a small, doubtful finding that a repeat CT could not settle, it can matter. Ask your oncologist which of those two situations you are in before you choose the scanner. Nobody should upgrade a scan on the strength of the word digital alone.

No, and this is the most common surprise on a PET-CT bill. The CT taken inside a PET-CT is usually a low-dose study without contrast, there to show where the tracer signal sits. It is not a renal protocol contrast CT, which is the scan kidney cancer is actually characterised and staged on. So if you have not already had one, you will need it as a separate study, billed separately. The same applies to an MRI where contrast cannot safely be given. Ask any centre quoting you a PET-CT price whether a diagnostic contrast CT is included. If the answer is vague, treat the quoted figure as incomplete.

It depends on the route and on where the scan is done. Eligible kidney cancer treatment may be largely covered under Aarogyasri and PMJAY at empanelled centres, and diagnostic imaging is often handled differently from admitted treatment, so it has to be checked rather than assumed. Health insurance frequently pays for scans done as part of an admission but treats an outpatient scan differently, and many policies require pre-authorisation. Because the PET-CT is performed at a specialist partner imaging centre, two questions have to be answered together: are you eligible, and is that centre empanelled or in your cashless network. Our team checks both and puts the expected out-of-pocket figure in writing before a date is fixed.

The imaging centre, in most cases. PET-CT is not delivered in house at CION. Like ablation and every kind of kidney surgery, it is carried out at a specialist partner imaging centre where it may also be billed, and CION coordinates it: the referral, the appointment, the tracer booking, and the review of the images afterwards alongside your other scans. What CION leads in house is the rest, which is most of it — the consultation, the contrast CT, ultrasound and MRI, the biopsy, the bloods and kidney function tests, the tumour board and your follow-up imaging. Knowing which invoice comes from where is the difference between a clear estimate and a surprise.

Almost certainly not. The higher priced PET-CT scans on a rate card, at ₹23,999, use tracers built for specific tumour biology — principally prostate cancer and neuroendocrine tumours. They are not the standard scan for kidney cancer, and paying for one because it sounds more advanced is money spent on the wrong question. The standard whole-body PET-CT uses a sugar-like tracer, and even that has real limitations in the kidney, because the tracer is cleared into the urine and the commonest kidney cancer often takes it up weakly. If a centre suggests an upgraded tracer for a kidney tumour, ask what decision it would change. If there is no clear answer, there is no reason to pay for it.